Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $66,600.00 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $6.66, for a total value of $66,600.00. Following the sale, the director now directly owns 76,294 shares in the company, valued at approximately $508,118.04. This trade represents a 11.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Monday, January 6th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.08, for a total value of $60,800.00.
• On Thursday, December 5th, Rosty Raykov sold 796 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.04, for a total value of $4,807.84.

Fennec Pharmaceuticals Price Performance

FENC opened at $6.65 on Friday. The company’s 50-day moving average is $6.12 and its 200 day moving average is $5.52. The firm has a market capitalization of $183.07 million, a PE ratio of -66.49 and a beta of 0.34. Fennec Pharmaceuticals Inc has a fifty-two week low of $3.96 and a fifty-two week high of $11.49.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its earnings results on Thursday, November 7th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. The firm had revenue of $6.97 million during the quarter, compared to analysts’ expectations of $9.13 million. During the same quarter in the prior year, the company earned ($0.07) EPS. As a group, analysts expect that Fennec Pharmaceuticals Inc will post -0.09 EPS for the current year.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of Fennec Pharmaceuticals in the 4th quarter worth approximately $97,000. Charles Schwab Investment Management Inc. increased its stake in shares of Fennec Pharmaceuticals by 10.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company’s stock worth $386,000 after purchasing an additional 5,694 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Fennec Pharmaceuticals by 12.9% during the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock valued at $217,000 after purchasing an additional 3,911 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Fennec Pharmaceuticals by 18.7% in the third quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock worth $74,000 after buying an additional 2,330 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Fennec Pharmaceuticals by 274.3% in the third quarter. Barclays PLC now owns 31,319 shares of the company’s stock worth $157,000 after buying an additional 22,951 shares in the last quarter. 55.51% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on FENC shares. Wedbush reiterated an “outperform” rating and issued a $13.00 price objective on shares of Fennec Pharmaceuticals in a report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Finally, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.